Jason Kukas
Psychiatric/Mental Health · Upland, CANPI 1437876760
Payments from drug & device makers
Across 226 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$808
- Otsuka America Pharmaceutical, Inc.$741
- AbbVie$610
- Vanda Pharmaceuticals Inc.$565
- Neurocrine Biosciences, Inc.$477
- plus $2K from 9 others
What the payments were for
- Food & beverage$5,934100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $1,030 |
| Alkermes, Inc. | 30 | $808 |
| Otsuka America Pharmaceutical, Inc. | 33 | $741 |
| AbbVie | 36 | $610 |
| Vanda Pharmaceuticals Inc. | 20 | $565 |
| Neurocrine Biosciences, Inc. | 11 | $477 |
| Supernus Pharmaceuticals, Inc. | 11 | $367 |
| Teva Pharmaceuticals USA, Inc. | 15 | $357 |
| Johnson & Johnson | 9 | $351 |
| E.r. Squibb & Sons, L.L.C. | 10 | $197 |
| Axsome Therapeutics, Inc. | 5 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $134 |
| Idorsia Pharmaceuticals US Inc | 3 | $61 |
| Lundbeck LLC | 2 | $32 |
| Almatica Pharma LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,946 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 17 | $23,633 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,763 |
| Aripiprazole | 47 | $3,399 |
| Trazodone Hcl | 66 | $870 |
| Lurasidone Hcl | 23 | $840 |
| Quetiapine Fumarate | 72 | $695 |
| Buspirone Hcl | 54 | $360 |
| Bupropion XlBupropion Hcl | 29 | $312 |
| Clonazepam | 58 | $246 |
| Prazosin Hcl | 16 | $242 |
| Gabapentin | 38 | $236 |
| Sertraline Hcl | 23 | $230 |
| Alprazolam | 17 | $177 |
| Hydroxyzine Hcl | 22 | $166 |
| Zolpidem Tartrate | 17 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $610 | $23,63317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $134 | $11,76323 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $23023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Upland
- Michael SolanoUpland$14K
- Percival BaldriasUpland$14K
- Tashana LewisUpland$12K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.